Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 13/20 | 0.48 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176806 | 1.00 | CHEK2 (0.51) | CHEK2UTS2RSLC5A7HTR2CHTR2B | |
| SCHEMBL5741829 | 0.86 | OPRK1 (0.55) | CHEK2UTS2RSLC5A7HTR2CHTR2B | |
| SCHEMBL5742254 | 0.86 | OPRK1 (0.55) | CHEK2UTS2RSLC5A7HTR2CHTR2B | |
| SCHEMBL7031287 | 0.86 | PDE4B (0.56) | CHEK2SLC5A7 | |
| SCHEMBL6177433 | 0.86 | OPRK1 (0.55) | CHEK2UTS2RSLC5A7HTR2CHTR2B | |
| SCHEMBL5741837 | 0.85 | CHEK2 (0.51) | CHEK2SLC5A7HTR2CHTR2B | |
| SCHEMBL5744137 | 0.81 | UTS2R (0.51) | CHEK2UTS2R | |
| SCHEMBL5742176 | 0.81 | UTS2R (0.51) | CHEK2UTS2R | |
| SCHEMBL5743838 | 0.80 | UTS2R (0.52) | UTS2RHTR2CHTR2B | |
| SCHEMBL5835364 | 0.80 | UTS2R (0.52) | UTS2RHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385840-B1 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | claimed |
| US-7091204-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | claimed |
| EP-1385840-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1385841-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040152891-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| US-20040142948-A1 | Sulfonamides | DHANAK DASHYANT (US) | 2004-07-22 | — | — | US | claimed |
| EP-1385840-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-04 | — | — | EP | claimed |
| EP-1385841-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002090353-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| WO-2002090348-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1385840-B1 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7091204-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1385840-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1385841-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040152891-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-20040142948-A1 | Sulfonamides | DHANAK DASHYANT (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1385840-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385841-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090353-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002090348-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152891-A1 | Sulfonamides | UTS2R, PRSS2, STS | CHEK2 4084/4885UTS2R 1/4885SLC5A7 3060/4885 |
| US-20040142948-A1 | Sulfonamides | UTS2R, PRSS2, STS | CHEK2 4084/4885UTS2R 1/4885SLC5A7 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.